AstraZeneca LP v. Breath Limited, No. 13-1312 (Fed. Cir. Oct. 30, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

AstraZeneca LP and AstraZeneca AB (“AstraZeneca”) appeal the district court’s judgment following a bench trial, holding that the asserted claims of AstraZeneca’s U.S. Patent No. 7,524,834 (“’834 Patent”) were not i n- fringed and that the asserted claims of U.S. Patent No. 6,598,603 (“’603 Patent”) were invalid as anticipated and obvious, thus ruling in favor of the defendants Breath Limited (“Breath”); Apotex, Inc. and Apotex Corp. (“Apo- tex”); Sandoz, Inc. (“Sandoz”); and Watson Laboratories, Inc. (“Watson”) (collectively “Appellees”).